Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

Approximately 40 U.S. sites will participate in the study in order to enroll approximately
500 patients over a year period. They will be recruited into two cohorts - the first episode
cohort and the early phase (EP) cohort, with approximately 250 patients in each cohort.
Enrollment of patients will be discontinued when the appropriate number for the target for
each cohort is reached.

After providing written informed consent, patients will be screened for general eligibility
by the clinical team at the site. Basic demographic data will be collected to determine
suitability for inclusion into the study. The site will complete an information interview
comprising data regarding symptomology and history, but the diagnosis of schizophrenia will
fall to a centralized, remote blinded rater to enable consistency for eligibility.

Prescribers at sites in the clinician's choice arm can treat the patients in the manner most
appropriate for that individual. Prescribers at sites in the Aripiprazole Once Monthly arm
monthly will prescribe and administer the medication according to recommendations contained
in the product labeling.

For a period of 2 years all subjects will receive bimonthly calls inquiring about visits to
emergency rooms and hospitalization. At 4 month intervals information on use of services,
insurance status, work, school attendance, and other service use outcomes will be assessed.

Inclusion Criteria:

Are able to provide written informed consent Have a confirmed diagnosis of schizophrenia as
defined by Diagnostic and Statistical Manual (DSM) 5 criteria using the SCID (Structured
Clinical Interview for DSM disorders) Are between the ages of 18 and 35, inclusive Have the
following history with antipsychotic medications

1. First episode subjects: < 1 year of lifetime exposure to antipsychotic medication and
only one episode of psychosis

2. EP subjects: between 1 year and 5 years of lifetime exposure to antipsychotic
medication or subjects with < 1 year of lifetime antipsychotic medication and more
than one episode of psychosis.

For LAI subjects: Must be willing to accept an injectable form of treatment

Exclusion Criteria:

Have a current primary DSM-5 diagnosis other than schizophrenia, including schizophreniform
disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium,
dementia, and amnestic or other cognitive disorders.

For LAI sites only - have a known allergy or intolerance to aripiprazole, or a past
negative response to aripiprazole that is not explained by nonadherence Be pregnant or
lactating Have any unstable medical condition that, in the opinion of the investigator,
would be detrimental to the subject or would confound the results of the study Subjects in
the MRI subset only- presence of any metal implants, pacemakers, irremovable prosthetic
devices, or other devices or situations that may preclude imaging